8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
Beam Therapeutics, a US biotech developing precision genetic medicines through base editing, has named Gopi Shanker its chief scientific officer (CSO). 22 March 2023
Primary overall survival (OS) analysis results of the Phase III ZUMA-7 study have been released by US biotech major Gilead Sciences’ subsidiary Kite. 22 March 2023
Australian Health Technology Assessment (HTA) Review Terms of Reference were released today, and will continue to advocate for bold policy reform to speed up access to innovative medicines. 22 March 2023
Positive data for a new kind of cancer med, targeting the CLDN18.2 biomarker, will be presented at the March Plenary Series of the American Society of Clinical Oncology (ASCO). 22 March 2023
Even as the World Trade Organization (WTO) members continue to remain divided on the waiver of intellectual property (IP) rights for Covid-related vaccine technologies, India, South Africa, and other developing countries have resuscitated their campaign to extend the temporary waiver of IP for Covid vaccines to coronavirus drugs at the WTO. 22 March 2023
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) said today it will introduce a series of new measures, with support from partners to make it faster and easier to gain approval and to run clinical trials in the UK. 21 March 2023
US psychiatric and neurological conditions specialist Karuna Therapeutics has announced top-line results from its Phase III EMERGENT-3 trial of its lead investigational therapy, KarXT (xanomeline-trospium) in schizophrenia. 21 March 2023
Sandoz, the soon to be spun-out generics and biosimilars unit of Swiss pharma giant Novartis, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration 21 March 2023
Zydus Lifesciences today revealed it has received final approval for Tofacitinib Tablets, 5mg and tentative approval for Tofacitinib Tablets, 10mg, generic versions of US pharma giant Pfizer’s Xeljanz from the US Food and Drug Administration (FDA). 21 March 2023
Drugmakers have welcomed the European Commission’s commitment to a “competitiveness check,” related to the legislative environment in the region. 21 March 2023
Just a couple of years ago, shares in US biotech Sangamo Therapeutics were worth more than $13, but the latest dose of bad news on the company has led them to drop below $2. 21 March 2023
US biotech major Gilead Sciences has exercised its option to exclusively license Nurix Therapeutics’ investigational targeted protein degrader molecule NX 0479, with the news sending the latter’s share price up 6.5% to $9.60 by late afternoon on Monday. 21 March 2023
Patient Voice Aotearoa’s Dr Malcolm Mulholland appeared before the Health Select Committee to voice opposition to parts of the Therapeutic Products Bill on behalf of patients in New Zealand. 21 March 2023
A novel combination medicine designed to help people with chronic refractory gout has demonstrated a high level of efficacy in a Phase III study. 21 March 2023
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.